These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

7179 related items for PubMed ID: 2905882

  • 21. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H.
    J Immunol; 1999 Jul 15; 163(2):583-9. PubMed ID: 10395644
    [Abstract] [Full Text] [Related]

  • 22. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
    Yoshioka T, Sato S, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1986 Aug 15; 77(8):825-32. PubMed ID: 3093429
    [Abstract] [Full Text] [Related]

  • 23. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):884-90. PubMed ID: 3257412
    [Abstract] [Full Text] [Related]

  • 24. Inhibitory effect of murine recombinant interferon (beta) on the pulmonary metastasis of B-16 melanoma.
    Sakurai M, Iigo M, Ozaki A, Jett JR, Sasaki Y, Hoshi A, Saijo N.
    Jpn J Cancer Res; 1986 Aug 15; 77(8):774-81. PubMed ID: 3093426
    [Abstract] [Full Text] [Related]

  • 25. Evidence that expression of asialo-GM1 may be associated with cell activation. Correlation of asialo-GM1 expression with increased total cellular RNA and protein content in normal thymocyte and spleen cell populations.
    Stout RD, Schwarting GA, Suttles J.
    J Immunol; 1987 Oct 01; 139(7):2123-9. PubMed ID: 2443562
    [Abstract] [Full Text] [Related]

  • 26. Precursor phenotype of lymphokine-activated killer cells in the mouse.
    Salup RR, Mathieson BJ, Wiltrout RH.
    J Immunol; 1987 Jun 01; 138(11):3635-9. PubMed ID: 3108370
    [Abstract] [Full Text] [Related]

  • 27. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun 01; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 28. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K, Tilden AB, Balch CM.
    J Immunol; 1986 May 15; 136(10):3910-5. PubMed ID: 3084648
    [Abstract] [Full Text] [Related]

  • 29. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
    Anderson TD, Hayes TJ, Gately MK, Bontempo JM, Stern LL, Truitt GA.
    Lab Invest; 1988 Nov 15; 59(5):598-612. PubMed ID: 3263543
    [Abstract] [Full Text] [Related]

  • 30. The antitumor effects of IFN- beta against human renal cell carcinoma in athymic nude mice.
    Shirahama T, Kayajima T, Ohi Y.
    In Vivo; 1989 Nov 15; 3(5):345-9. PubMed ID: 2519876
    [Abstract] [Full Text] [Related]

  • 31. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 15; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 32. Intraepithelial leukocytes contain a unique subpopulation of NK-like cytotoxic cells active in the defense of gut epithelium to enteric murine coronavirus.
    Carman PS, Ernst PB, Rosenthal KL, Clark DA, Befus AD, Bienenstock J.
    J Immunol; 1986 Mar 01; 136(5):1548-53. PubMed ID: 3005395
    [Abstract] [Full Text] [Related]

  • 33. Expression of asialo GM1 by both Thy-1-positive and Thy-1-negative lymphocytes: evidence for modification of asialo GM1 by sialic acid.
    Harris MT, Schwarting GA, Stout RD.
    Thymus; 1981 Sep 01; 3(3):169-84. PubMed ID: 6171919
    [Abstract] [Full Text] [Related]

  • 34. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
    Silagi S, Dutkowski R, Schaefer A.
    Int J Cancer; 1988 Feb 15; 41(2):315-22. PubMed ID: 3123404
    [Abstract] [Full Text] [Related]

  • 35. Expression of asialo GM1 on a subset of adult murine thymocytes: histological localization and demonstration that the asialo GM1-positive subset contains both the functionally mature and the proliferating thymocyte subpopulations.
    Suttles J, Schwarting GA, Hougland MW, Stout RD.
    J Immunol; 1987 Jan 15; 138(2):364-72. PubMed ID: 3098839
    [Abstract] [Full Text] [Related]

  • 36. The effects of polyinosinic:polycytidylic acid (pI:C) on the graft-vs-host (GVH) reaction. II. Increased NK-mediated rejection on C57BL/6 lymphocytes by (C57BL/6 X A)F1 mice.
    Peres A, Nestel FP, Seemayer TA, Lapp WS.
    J Immunol; 1986 Dec 01; 137(11):3420-7. PubMed ID: 3537120
    [Abstract] [Full Text] [Related]

  • 37. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities.
    Stitz L, Baenziger J, Pircher H, Hengartner H, Zinkernagel RM.
    J Immunol; 1986 Jun 15; 136(12):4674-80. PubMed ID: 3486908
    [Abstract] [Full Text] [Related]

  • 38. Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM1.
    Charley MR, Mikhael A, Bennett M, Gilliam JN, Sontheimer RD.
    J Immunol; 1983 Nov 15; 131(5):2101-3. PubMed ID: 6355291
    [Abstract] [Full Text] [Related]

  • 39. Effect of rIFN-gamma and IL-2 treatments in mouse and nude rat infections with Toxoplasma gondii.
    Benedetto N, Auriault C, Darcy F, Lando D, Watier H, Capron A.
    Eur Cytokine Netw; 1991 Nov 15; 2(2):107-14. PubMed ID: 1813013
    [Abstract] [Full Text] [Related]

  • 40. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 359.